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Introduction: Current management of primary
spontaneous pneumothorax (PSP) is variable, with
little evidence from randomised controlled trials to
guide treatment. Guidelines emphasise intervention in
many patients, which involves chest drain insertion,
hospital admission and occasionally surgery.
However, there is evidence that conservative
management may be effective and safe, and it may
also reduce the risk of recurrence. Significant
questions remain regarding the optimal initial
approach to the management of PSP.
Methods and analysis: This multicentre,
prospective, randomised, open label, parallel group,
non-inferiority study will randomise 342 participants
with a first large PSP to conservative or interventional
management. To maintain allocation concealment,
randomisation will be performed in real time by
computer and stratified by study site. Conservative
management will involve a period of observation prior
to discharge, with intervention for worsening
symptoms or physiological instability. Interventional
treatment will involve insertion of a small bore drain.
If drainage continues after 1 hour, the patient will be
admitted. If drainage stops, the drain will be clamped
for 4 hours. The patient will be discharged if the lung
remains inflated. Otherwise, the patient will be
admitted. The primary end point is the proportion of
participants with complete lung re-expansion by
8 weeks. Secondary end points are as follows: days in
hospital, persistent air leak, predefined complications
and adverse events, time to resolution of symptoms,
and pneumothorax recurrence during a follow-up
period of at least 1 year. The study has 95% power to
detect an absolute non-inferiority margin of 9%,
assuming 99% successful expansion at 8 weeks in
the invasive treatment arm. The primary analysis will
be by intention to treat.
Ethics and dissemination: Local ethics approval
has been obtained for all sites. Study findings will be
disseminated by publication in a high-impact
international journal and presentation at major
international Emergency Medicine and Respiratory
meetings.
Trial registration number: ACTRN12611000184976;
Pre-results.
INTRODUCTION
Primary spontaneous pneumothorax (PSP) is
a signiﬁcant global health problem affecting
adolescents and young adults. The incidence
of PSP is around 18–28/100 000 per year
for men and 1.2–6/100 000 per year for
women.1 2 It usually occurs in the absence of
underlying lung disease or trauma; however,
anatomical abnormalities such as subpleural
blebs are present in up to 90% of cases.3 4
Tobacco smoking is a major risk factor,
and otherwise healthy male smokers have a
Strengths and limitations of this study
▪ This will be the largest randomised trial of the
management of large primary spontaneous
pneumothorax (PSP) that includes long-term
follow-up.
▪ The study includes an assessment of efficacy,
safety, healthcare usage and patient-centred out-
comes such as pain and return to work.
▪ The findings will provide high-level evidence for
the optimum initial management of PSP and will
be generalisable to clinical practice internationally.
▪ The nature of the treatments being compared
means that blinding of participants to treatment
allocation is not possible; however, the ability for
patients to decline involvement combined with
unbreakable allocation concealment means that
participant and clinician bias towards one treat-
ment modality or another is less likely to con-
found the study results.
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9–22-fold greater relative risk of developing PSP com-
pared with non-smokers.5 Smoking is also associated
with a higher recurrence rate.6
The current management of PSP is variable, with
sparse evidence from randomised controlled trials to
guide treatment.7 Current guidelines from Britain and
North America emphasise the importance of interven-
tion in most patients. This may involve insertion of a
chest drain, hospital admission and the need for thor-
acic surgery in some individuals.8 9 This invasive
approach has recently been questioned.10
Throughout the early 20th century, the treatment of
PSP was predominantly conservative, with bed rest for
most patients, and invasive treatment reserved for
severely symptomatic episodes.11–17 In 1966, the ﬁrst
large series of patients with PSP who had conservative
community management was published.18 Sixty-eight
patients aged between 15 and 44 years with large and
small PSPs were discharged and managed in the com-
munity without intervention. Re-expansion was observed
in 78% by 4 weeks and in 97% by 8 weeks. Although not
a randomised controlled trial, this case series suggested
that discharging patients without intervention was safe
and effective. A conservative initial approach to PSP has
since been suggested by others.19 20 Despite this, rates of
intervention in PSP have steadily increased over subse-
quent decades. The reasons that an interventional
approach has become standard practice are unclear. It
may relate to the increasing ease of tube insertion,
better tube design and also physicians perceiving a need
to actively evacuate the air. In addition, there is a per-
ception that PSP is potentially serious because of the
theoretical risk of tension pneumothorax. Hence, inter-
vention may be considered a safer approach. However,
case series do not support the assertion that conservative
treatment is less safe.18–22
Interestingly, the rate of pneumothorax recurrence
among patients managed conservatively in the 1966
study was only 6% after 2 years and 11% after 4 years,
strikingly lower than more recent data from invasively
managed patients. In the last 10–15 years, prospective
studies of patients with PSP undergoing procedures
report cumulative 1-year recurrence rates of 23–27%.23–26
One possible mechanism for a lower recurrence rate
with conservative management is that healing of the
pleural defect may be facilitated by allowing the lung to
stay collapsed initially followed by slow re-expansion.10
Although PSP may be associated with pain and short-
ness of breath, the symptoms are variable and improve
quickly. Patients are often asymptomatic after 24–48
hours,18 and 46% of them wait more than 2 days before
presenting for medical assessment.27
There are a number of issues regarding the current
established practice of intervention in PSP. From a
patient perspective, the insertion of a chest drain is a
painful procedure; in one study, 50% of patients experi-
enced pain levels of 9–10 on a scale of 10.28 Chest drain
insertion has a number of important complications such
as injury to organs, bleeding and infection. Concern
about these complications remains, even with the use of
modern small bore chest drains.29 The management of
an underwater seal drain requires hospital admission,
and hence time off work or away from other duties, with
an average length of stay of around 4 days.23 30 If the air
leak continues beyond 3–5 days, patients often proceed
to surgery, with its attendant costs and potential harms.
In summary, signiﬁcant questions remain regarding
the optimal initial approach to the management of large
PSP.31 In the absence of a well-conducted, randomised,
controlled trial, it is unlikely that clinicians will change
current practice which has been entrenched for decades
and is re-enforced by current international guidelines. If
completed, this study will be the largest international
trial in PSP ever undertaken and will be the ﬁrst to
address the fundamental management question of con-
servative versus invasive management of PSP.
Aims and hypotheses
Our main aim is to determine whether conservative
management of large PSP is an effective and acceptable
therapeutic option. Our hypotheses are as follows:
▸ The resolution of large PSP will be similar after
8 weeks with either therapeutic regimen.
▸ Conservative management will be associated with
shorter times to recovery due to a reduced risk of per-
sistent air leak, higher levels of patient satisfaction
and reduced intervention-related morbidity.
▸ Conservative management lowers the risk of PSP recur-
rence due to improved healing of the lung defect.
METHODS AND ANALYSIS
Study design
This is a multicentre, prospective, randomised, con-
trolled, open label parallel group, non-inferiority study
of conservative versus invasive treatment of PSP. It will
involve the randomisation of 342 participants presenting
to an Emergency Department (ED) in Australia and
New Zealand with a PSP.
Screening and selection
After the radiological diagnosis of PSP has been con-
ﬁrmed, and eligibility assessed, potential participants will
be approached by ED or Respiratory Medicine clinicians
about the possibility of taking part in the study. The
doctor will give an initial overview of the study and then
provide the study participant information and consent
form (PICF) to read. Time will be allowed for the par-
ticipant to ask questions about the study. Study enrol-
ment will only occur following the completion of the
informed consent process. Potential participants will be
made aware that their clinical management will not be
affected by their decision to either take part or decline
study participation, and that they can withdraw at any
time. All sites will maintain screening logs of potentially
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suitable cases of pneumothorax that were not enrolled
noting the reasons for exclusion.
Inclusion criteria
PSP that is 32% or larger by the method of Collins,32
that is a ‘sum of interpleural distances’ (A+B+C) of 6 cm
or greater.
Exclusion criteria
▸ Previous spontaneous pneumothorax on the same
side;
▸ Secondary pneumothorax, deﬁned as pneumothorax
occurring in the setting of acute trauma (including
iatrogenic) or underlying lung disease including but
not limited to COPD, pulmonary ﬁbrosis, TB, cystic
ﬁbrosis, lung cancer and asthma that requires regular
preventative medication or has been symptomatic
(eg, nocturnal symptoms) within the past 2 years;
▸ Coexistent haemothorax;
▸ Bilateral pneumothorax;
▸ Physiological instability suggesting tension pneumo-
thorax: systolic BP (SBP) <90 mm Hg, mean arterial
pressure <65 mm Hg or HR ≥ SBP (ie, shock index
HR/SBP ≥1);
▸ Age <14 years;
▸ Age >50 years (due to a higher incidence of under-
lying lung disease, ie, secondary pneumothorax);
▸ Pregnancy at the time of enrolment. All women of
reproductive age will have a pregnancy test;
▸ Circumstances whereby the patient either does not
have adequate support after discharge to re-attend
hospital if required, or is unlikely to present for study
follow-up;
▸ Air travel within the next 12 weeks if this cannot be
deferred should the pneumothorax be slow to
resolve.
Randomisation
Participants who fulﬁl the eligibility criteria and give
informed consent will be randomised 1:1 to receive
either conservative or invasive management. To maintain
allocation concealment, participants will be randomised
in real time, stratiﬁed by study site, using an adaptive
biased coin (Urn) technique to maintain balance alloca-
tion at each site.33 The University of Western Australia
will host the web-based randomisation system (Filemaker
Server Advanced, Filemaker, Santa Clara, California,
USA).
Owing to the nature of the interventions, it will not be
possible to blind participants or investigators to treat-
ment allocation. However, all study chest x-rays (CXR)
which determine the primary outcome measure will be
read by a radiologist blinded to all participant details.
Initial clinical care
The initial management received by participants prior
to their randomisation will be as follows:
1. Oxygen as required (if SpO2 <92% on room air).
2. Initial analgesia if required:
▸ Mild–moderate pain: paracetamol 1 g, plus a non-
steroidal anti-inﬂammatory drug (NSAID), for
example, ibuprofen 400–800 mg, if there are no
contraindications to NSAID.
▸ Severe pain: paracetamol and an NSAID as for
mild–moderate pain plus intravenous morphine
with an initial bolus of 0.1 mg/kg (5–10 mg) with
further doses titrated to effect, followed by one
dose of oral narcotic (eg, oxycodone 5 mg orally).
Conservative treatment protocol
1. Participants will be observed for 4 hours and then a
repeat CXR performed prior to discharge from the
ED (ﬁgure 1).
2. Prior to discharge, participants must be able to walk
comfortably around the ED to ensure that they are
capable of undertaking routine activities of daily living.
3. Participants will switch to the invasive protocol if
A. Signiﬁcant symptoms persist despite adequate
analgesia: chest pain and/or dyspnoea that is
likely to prevent routine activities of daily living or
such that the participant is unwilling to continue
conservative treatment.
B. Physiological instability develops during the
observation period: SBP <90 mmHg, HR ≥ SBP,
respiratory rate (RR) >30/min, and SpO2 <90% on
room air.
C. The repeat CXR shows that the pneumothorax is
increasing in size, and there has been a trend in
observations to suggest the development of
tension. NB an increase in pneumothorax size on
CXR alone does not necessarily require interven-
tion if the participant’s clinical condition has
improved or has remained stable.
4. Participants will be prescribed discharge analgesia
according to their requirements while in ED: para-
cetamol, ± NSAID ± a short supply of oral narcotic.
5. Written discharge instructions will be provided; these
include what to do in the event of deterioration and
advice not to scuba dive or ﬂy.
6. At any stage during follow-up if the participant has
signiﬁcant symptoms (as deﬁned above), the investi-
gator may elect to switch them to the interventional
protocol.
INTERVENTIONAL TREATMENT PROTOCOL
1. A small bore (≤12 F) Seldinger-style chest drain will
be inserted in either the second intercostal space
mid-clavicular line anteriorly or the safety triangle lat-
erally. The drain will be attached to an underwater
seal. Suction will not be applied (ﬁgure 1).
2. A repeat CXR will be performed 1 hour after drain
insertion. If the lung has re-expanded (pneumo-
thorax now small with a sum of interpleural distances
<6 cm), and there has been a reduction in symptoms
if present initially, and the underwater drain is no
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longer bubbling, the drain will be closed using a
three-way tap and the patient observed for 4 hours.
After 4 hours, if the pneumothorax size is stable on
repeat CXR, and the participant remains clinically
stable, the drain will be removed. Simple analgesia will
be prescribed for residual symptoms, written discharge
instructions provided and the participant discharged.
3. If initial drain insertion does not result in pneumo-
thorax resolution, or the pneumothorax recurs
under observation,
Figure 1 Flow diagrams for conservative and interventional treatment protocols.
4 Brown SGA, et al. BMJ Open 2016;6:e011826. doi:10.1136/bmjopen-2016-011826
Open Access
group.bmj.com on June 5, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
A. The three-way tap will be opened and underwater
seal drainage will restart.
B. Participants will be admitted under an appropri-
ate inpatient team according to local protocols
(General Medicine, Cardiothoracic Surgery or
Respiratory Medicine). Subsequent interventions
(additional drains, suction and requirement for
surgery) will be at the discretion of the treating
inpatient team.
C. Prior to discharge, a CXR will be performed after
removal of all chest drains.
Follow-up assessments
Initial follow-ups at 24–72 hours, 2 weeks, 4 weeks and
8 weeks will be carried out face to face wherever pos-
sible, but can be carried out over the telephone if neces-
sary with the investigator making arrangements with the
patient to have CXR and spirometry performed. The
reasons for missing or incomplete data will be noted. All
participants will have the following assessments:
▸ Clinical review and datasheet completion at 24–
72 hours, 2 weeks, 4 weeks and 8 weeks after enrol-
ment. If the participant cannot attend the scheduled
clinical review, completion of the follow-up question-
naire will be carried out over the telephone.
▸ A CXR will be undertaken at 2, 4 and 8 weeks until
pneumothorax resolution.
▸ Spirometry (FEV1, FVC, height and weight) will be
performed after pneumothorax resolution.
▸ Participants will be telephoned at 6 and 12 months
post-enrolment and then yearly for up to 5 years.
Pneumothorax recurrence and other follow-up data
will be collected, including study-related adverse
events (AE). In addition, a search of Clinical
Information Systems, and admission and ED attend-
ance records, will be undertaken at these time points.
Study measurements
▸ Age, sex and smoking history.
▸ Date and time of symptom onset, presentation to ED,
randomisation and discharge.
▸ Pneumothorax size using the method described by
Collins et al32 for each study CXR. A single reporting
radiologist will perform a blinded interpretation cen-
trally, on large batches of de-identiﬁed CXRs pre-
sented in random sequence without date or time
stamps to minimise any association between interven-
tion and ﬁnal outcome.
▸ Chest pain (verbal analogue) and dyspnoea (Borg
scale) scores will be recorded at each study contact.
▸ Times of last chest pain, dyspnoea and use of anal-
gesia will be recorded at each study contact.
▸ All procedures, including the date and time, will be
recorded.
▸ Predeﬁned complications and AE will be recorded:
1. Tension pneumothorax;
2. Haemothorax;
3. Trauma to the heart, liver, spleen or bowel;
4. Foreign body in chest wall;
5. Foreign body in chest cavity;
6. Infection of the skin and subcutaneous tissues
requiring treatment with antibiotics;
7. Infection of the pleural space (empyema) requir-
ing treatment with antibiotics;
8. Pneumonia requiring treatment with antibiotics;
9. Sepsis, deﬁned as likely infection and at least two
of the following: temperature >38°C or <36°C, HR
>90 bpm, RR >20/min, white cell count (WCC)
>12 or <4×109/L;
▸ Other complications;
▸ Numbers of CXRs and chest CTs performed;
▸ Details of unplanned attendances relating to
pneumothorax until 8 weeks after enrolment;
▸ Patient satisfaction at 8 weeks;
▸ Days of work or study lost by 8 weeks;
▸ Pneumothorax recurrence. Deﬁned as a pneumo-
thorax on the same side on a CXR performed
AFTER a CXR has conﬁrmed complete resolution at
least 24 hours after the removal of all catheters/
drains. Any re-accumulation prior to this will be
attributed to the initial pneumothorax (ie, ongoing
leak) rather than a recurrence.
Primary outcome
The proportion of participants with complete lung
re-expansion by 8 weeks.
Secondary outcomes
▸ Persistent air leak, deﬁned by the presence of a chest
drain for 3 days or longer,
▸ Pneumothorax recurrence,
▸ Time to symptomatic recovery deﬁned as: discharge
from hospital and resolution of symptoms and cessa-
tion of analgesic medication,
▸ Complications and AE as deﬁned above,
▸ Hospital bed days,
▸ Number of procedures and investigations,
▸ Days off work,
▸ Patient satisfaction at 8 weeks.
Data collection, storage and verification
Data will be recorded in paper case report forms at the
time of each patient contact. These will be faxed to the
study lead site for checking followed by entry into the
secure study database. Original datasheets will be
securely stored at each site according to local ethics pro-
tocols. Research staff from the lead site will perform site
visits and source data veriﬁcation.
Statistical analysis
The primary outcome of lung re-expansion by 8 weeks
will be analysed using a non-inferiority approach (ie,
one-tailed α=0.05). Logistic regression will determine
the effects of the randomised treatment, conservative
versus intervention.
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As a secondary analysis, the potential confounding and
interaction effects of age, smoking status and initial
pneumothorax size on dichotomous outcomes will be
examined. Site will be included in the primary analysis as a
categorical variable. Cox proportional hazards regression
will be used to analyse time interval outcomes (recovery
and pneumothorax recurrence). The primary analysis will
be by intention to treat (ITT). Patients initially allocated to
conservative treatment that switch to invasive treatment
will remain in their original group for the purpose of ITT.
Per-protocol analyses will also be performed.
POWER CALCULATION
A sample size of 274 has the ability to detect an absolute
non-inferiority margin of 9%, assuming 99% successful
expansion by 8 weeks in the invasive intervention group
with a one-tailed α of 5% and a power of 95%. This
represents a 90% successful expansion rate with conser-
vative treatment, that is, a failure rate of ∼1 in 10. In
other words, we wish to rule out a re-expansion rate of
<90% after 8 weeks with 95% power. The relatively high
power has been chosen in order to minimise the chance
of failing to conﬁrm our hypotheses of non-inferiority
with a clinically relevant margin, for a treatment that
may be highly desirable to patients. High study power is
recommended for non-inferiority studies.34 Allowing for
a dropout rate of up to 20%, we plan to recruit 342 par-
ticipants. However, this number may be adjusted accord-
ing to the actual number of dropouts observed.
Ethics approvals, data and safety monitoring
Local ethics approval has been obtained for all recruit-
ing sites. Written informed consent will be obtained
before any study activity or intervention according to
International Conference on Harmonisation (IHC)
Good Clinical Practice (GCP), and regulatory and legal
requirements. Each signature will be personally dated by
each signatory or the participant’s legally accepted rep-
resentative. The consent form and all study case report
forms will be securely retained by the investigator as part
of the study records. All participants or the participant’s
legally accepted representative will receive a copy of the
signed consent form.
All participants will be informed that their personal
study-related data will be used by the principal investiga-
tor in accordance with the local data protection law. All
participants will be informed that their medical records
may be examined by authorised monitors or clinical
auditors appointed by appropriate ethics committee
members and by inspectors from regulatory authorities.
Data will be collected at each trial visit regarding any
AE and serious AE as deﬁned by the IHC GCP guide-
lines. All serious AE causally related to treatment proce-
dures will be reported to the relevant ethics committees,
the lead site and the independent Data and Safety
Monitoring Committee (DSMC) for their review and
recommendations. The DSMC comprises independent
clinicians with an interest in pneumothorax and a statis-
tician. Overview is carried out through the review of AE
and serious AE, all of which are reported at the regular
committee meetings. Each meeting determines the
Board’s recommendation to the Steering Committee as
to whether the study is safe to continue.
The trial is registered with the Australia New Zealand
Clinical Trials Registry—ACTRN12611000184976.
Dissemination
Study ﬁndings will be disseminated by publication in
an international journal and presentations at inter-
national Emergency Medicine and Respiratory Medicine
meetings.
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